Etoricoxib-induced toxic epidermal necrolysis: A fatal case report

Cyclooxygenase inhibitors were developed in the quest of enhanced analgesic efficacy devoid of gastric side effects. High usage of etoricoxib by prescription as well as self-administered routes has led to increasing reports of side effects and adverse reactions including dermatologic reactions in 0....

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Sukalyan Saha, Mukherjee, Shatavisa, Era, Nikhil, Mukherjee, Mala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106123/
https://www.ncbi.nlm.nih.gov/pubmed/30166751
http://dx.doi.org/10.4103/ijp.IJP_39_17
_version_ 1783349719784751104
author Roy, Sukalyan Saha
Mukherjee, Shatavisa
Era, Nikhil
Mukherjee, Mala
author_facet Roy, Sukalyan Saha
Mukherjee, Shatavisa
Era, Nikhil
Mukherjee, Mala
author_sort Roy, Sukalyan Saha
collection PubMed
description Cyclooxygenase inhibitors were developed in the quest of enhanced analgesic efficacy devoid of gastric side effects. High usage of etoricoxib by prescription as well as self-administered routes has led to increasing reports of side effects and adverse reactions including dermatologic reactions in 0.1%–0.3% of cases. The present report enumerates a case of toxic epidermal necrolysis induced by etoricoxib.
format Online
Article
Text
id pubmed-6106123
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-61061232018-08-30 Etoricoxib-induced toxic epidermal necrolysis: A fatal case report Roy, Sukalyan Saha Mukherjee, Shatavisa Era, Nikhil Mukherjee, Mala Indian J Pharmacol Drug Watch Cyclooxygenase inhibitors were developed in the quest of enhanced analgesic efficacy devoid of gastric side effects. High usage of etoricoxib by prescription as well as self-administered routes has led to increasing reports of side effects and adverse reactions including dermatologic reactions in 0.1%–0.3% of cases. The present report enumerates a case of toxic epidermal necrolysis induced by etoricoxib. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6106123/ /pubmed/30166751 http://dx.doi.org/10.4103/ijp.IJP_39_17 Text en Copyright: © 2018 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Drug Watch
Roy, Sukalyan Saha
Mukherjee, Shatavisa
Era, Nikhil
Mukherjee, Mala
Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
title Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
title_full Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
title_fullStr Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
title_full_unstemmed Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
title_short Etoricoxib-induced toxic epidermal necrolysis: A fatal case report
title_sort etoricoxib-induced toxic epidermal necrolysis: a fatal case report
topic Drug Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106123/
https://www.ncbi.nlm.nih.gov/pubmed/30166751
http://dx.doi.org/10.4103/ijp.IJP_39_17
work_keys_str_mv AT roysukalyansaha etoricoxibinducedtoxicepidermalnecrolysisafatalcasereport
AT mukherjeeshatavisa etoricoxibinducedtoxicepidermalnecrolysisafatalcasereport
AT eranikhil etoricoxibinducedtoxicepidermalnecrolysisafatalcasereport
AT mukherjeemala etoricoxibinducedtoxicepidermalnecrolysisafatalcasereport

Ejemplares similares